Literature DB >> 16509032

Classification of mutations in the human CD40 ligand, gp39, that are associated with X-linked hyper IgM syndrome.

J Bajorath1, K Seyama, S Nonoyama, H D Ochs, A Aruffo.   

Abstract

The interaction between the T cell activation antigen gp39 and CD40, its receptor CD40 on B cells, plays a critical role in the regulation of humoral immune responses. Using a detailed three-dimensional model of the gp39 extracellular region, we have analyzed 20 mutations in gp39 that were, with one exception, isolated from patients with X-linked hyper IgM (XHIM) syndrome. On the basis of this analysis, the mutations were classified according to their predicted locations and effects. Twelve mutations are thought to compromise the gp39 structure by affecting interactions in hydrophobic core regions or at monomer interfaces, whereas seven others map closely to gp39 residues important for interaction with CD40. The latter mutations may thus, directly or indirectly, interfere with CD40 binding. One naturally occurring mutant whose carrier displays normal immune responses maps to a solvent-exposed position in a loop region of the molecule.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 16509032      PMCID: PMC2143372          DOI: 10.1002/pro.5560050316

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  25 in total

Review 1.  CD40 and its ligand, an essential ligand-receptor pair for thymus-dependent B-cell activation.

Authors:  R J Noelle; J A Ledbetter; A Aruffo
Journal:  Immunol Today       Date:  1992-11

2.  Expression of a 32-kDa ligand for the CD40 antigen on activated human T lymphocytes.

Authors:  P Hermann; D Blanchard; B de Saint-Vis; F Fossiez; C Gaillard; B Vanbervliet; F Brière; J Banchereau; J P Galizzi
Journal:  Eur J Immunol       Date:  1993-04       Impact factor: 5.532

3.  The interpretation of protein structures: estimation of static accessibility.

Authors:  B Lee; F M Richards
Journal:  J Mol Biol       Date:  1971-02-14       Impact factor: 5.469

4.  CD40 ligand mutations in x-linked immunodeficiency with hyper-IgM.

Authors:  J P DiSanto; J Y Bonnefoy; J F Gauchat; A Fischer; G de Saint Basile
Journal:  Nature       Date:  1993-02-11       Impact factor: 49.962

5.  A 3-D model for the CD40 ligand predicts that it is a compact trimer similar to the tumor necrosis factors.

Authors:  M C Peitsch; C V Jongeneel
Journal:  Int Immunol       Date:  1993-02       Impact factor: 4.823

6.  Cloning of TRAP, a ligand for CD40 on human T cells.

Authors:  D Graf; U Korthäuer; H W Mages; G Senger; R A Kroczek
Journal:  Eur J Immunol       Date:  1992-12       Impact factor: 5.532

7.  CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome.

Authors:  R C Allen; R J Armitage; M E Conley; H Rosenblatt; N A Jenkins; N G Copeland; M A Bedell; S Edelhoff; C M Disteche; D K Simoneaux
Journal:  Science       Date:  1993-02-12       Impact factor: 47.728

8.  Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM.

Authors:  U Korthäuer; D Graf; H W Mages; F Brière; M Padayachee; S Malcolm; A G Ugazio; L D Notarangelo; R J Levinsky; R A Kroczek
Journal:  Nature       Date:  1993-02-11       Impact factor: 49.962

9.  The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome.

Authors:  A Aruffo; M Farrington; D Hollenbaugh; X Li; A Milatovich; S Nonoyama; J Bajorath; L S Grosmaire; R Stenkamp; M Neubauer
Journal:  Cell       Date:  1993-01-29       Impact factor: 41.582

10.  Recombinant human CD40 ligand stimulates B cell proliferation and immunoglobulin E secretion.

Authors:  M K Spriggs; R J Armitage; L Strockbine; K N Clifford; B M Macduff; T A Sato; C R Maliszewski; W C Fanslow
Journal:  J Exp Med       Date:  1992-12-01       Impact factor: 14.307

View more
  14 in total

1.  Crystallographic and mutational analysis of the CD40-CD154 complex and its implications for receptor activation.

Authors:  Hyun-Jung An; Young Jin Kim; Dong Hyun Song; Beom Suk Park; Ho Min Kim; Ju Dong Lee; Sang-Gi Paik; Jie-Oh Lee; Hayyoung Lee
Journal:  J Biol Chem       Date:  2011-02-01       Impact factor: 5.157

Review 2.  The hyper-IgM (HIM) syndrome.

Authors:  N Ramesh; M Seki; L D Notarangelo; R S Geha
Journal:  Springer Semin Immunopathol       Date:  1998

3.  CD40 ligand (CD154) stimulation of macrophages to produce HIV-1-suppressive beta-chemokines.

Authors:  R S Kornbluth; K Kee; D D Richman
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

4.  Proinflammatory responses induced by CD40 in retinal endothelial and Müller cells are inhibited by blocking CD40-Traf2,3 or CD40-Traf6 signaling.

Authors:  Jose-Andres C Portillo; Isaac Schwartz; Simona Zarini; Reena Bapputty; Timothy S Kern; Rose A Gubitosi-Klug; Robert C Murphy; M Cecilia Subauste; Carlos S Subauste
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-12-04       Impact factor: 4.799

Review 5.  Mutation analysis in primary immunodeficiency diseases: case studies.

Authors:  Amy P Hsu; Thomas A Fleisher; Julie E Niemela
Journal:  Curr Opin Allergy Clin Immunol       Date:  2009-12

6.  Leukocyte transfusion-associated granulocyte responses in a patient with X-linked hyper-IgM syndrome.

Authors:  T P Atkinson; C A Smith; Y M Hsu; E Garber; L Su; T H Howard; J T Prchal; M P Everson; M D Cooper
Journal:  J Clin Immunol       Date:  1998-11       Impact factor: 8.317

7.  CD40 promotes the development of early diabetic retinopathy in mice.

Authors:  Jose-Andres C Portillo; Jennifer A Greene; Genevieve Okenka; Yanling Miao; Nader Sheibani; Timothy S Kern; Carlos S Subauste
Journal:  Diabetologia       Date:  2014-10       Impact factor: 10.122

8.  CD40 induces anti-Toxoplasma gondii activity in nonhematopoietic cells dependent on autophagy proteins.

Authors:  Jennifer Van Grol; Luis Muniz-Feliciano; Jose-Andres C Portillo; Vera L Bonilha; Carlos S Subauste
Journal:  Infect Immun       Date:  2013-03-18       Impact factor: 3.441

9.  Three novel mutations reflect the variety of defects causing phenotypically diverse X-linked hyper-IgM syndrome.

Authors:  E López-Granados; R Cambronero; A Ferreira; G Fontán; M C García-Rodríguez
Journal:  Clin Exp Immunol       Date:  2003-07       Impact factor: 4.330

Review 10.  X-linked immunodeficiency with hyper-IgM (XHIM).

Authors:  L D Notarangelo; A R Hayward
Journal:  Clin Exp Immunol       Date:  2000-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.